Navigation Links
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW

+1 815 210 0107 Matthew Cabrey (Shire) +1 484 595 8248

GIULIANI SpA

Giuliani SpA, founded in 1889, is a privately owned specialty biopharmaceutical company strategically focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn's disease, food intolerances and dermatological disorders. Giuliani's R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

COSMO Pharmaceuticals SpA

Cosmo is a speciality pharma company that aims to become a global leader in optimized therapies for certain gastrointestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn's disease, and colon infections. Cosmo's most advanced development product is LIALDA(TM)/ MEZAVANT(TM), a treatment for ulcerative colitis that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX Technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: http://www.cosmopharmaceuticals.com.

Digestive Disease Week

DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Societ
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
(Date:11/28/2008)... Germany, November 28 German biote...hip in specialized HIV monitoring and,AIDS patien...g countries. In,the year 2008, 2.5 million patien...bust and highly affordable "CyFlow" system, suppor...th HIV/AIDS. Due to introduction of the,Partec in...
(Date:11/26/2008)...nn., Nov. 26 Children w...significantly increased risk of developing mental ...of a Mayo Clinic study published this month in Pe...ademy of Pediatrics. , , The retrospective ... with strabismus (misaligned eyes) and compared th...
(Date:11/25/2008)...ness can improve recovery , , Audio and Web...able on the Mayo Clinic News Blog. Please see the ... ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewswire...e patients don,t think they,re having a stroke -- ...heir condition worsens. The findings appear in the...
(Date:11/25/2008)...NCISCO, Calif., Nov. 25 Proteolix,...of novel therapeutics that target,protein degrada...oday,announced that data from two ongoing Phase 2...ma will be presented at the upcoming 50th Annual M...). Carfilzomib is the first in a new class,of sp...
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Eye Divergence in Children Triples Risk of Mental Illness 2Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 1Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 2Homeland Security awards 2 grants to Rutgers for nuclear threat detection 422 3Fund Manager Joins Board of GSI Securitization Inc 1368 1Fund Manager Joins Board of GSI Securitization Inc 1368 2Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 1Billians HealthDATA GM Speaking on Dreamforce 07 Panel 1363 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 1CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 2CryoLife Signs Distribution Agreement for Inclusion of BioGlue 28R 29 Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes 614 3
...g therapeutic cancer vaccine,trials have yet to sh... immune system to shrink tumors -- yet patients wh...nger and respond,better to subsequent treatment. I...journal of the American Association for Cancer,Res...hers asks a,fundamental question: are we looking a...
...)--Jul 5, 2007 - Australian,biotechnology company ...apricitabine,s controlled, double blinded phase wh...ase IIb trial.,Patients have now progressed into t...) and will continue to receive 800mg,apricitabine ...e.,The Company expects to release results from the...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: